Group 1 - The core adjustment of the indices reflects a shift towards high-quality stocks and market representation, with specific companies being added or removed based on their market capitalization and operational stability [1][2] - The inclusion of companies like Chip Source Microelectronics and Huada Gene reflects a trend towards innovation-driven economic transformation, focusing on high-end manufacturing and technological innovation [2][3] - The adjustments serve as a "vote" from the capital market on industry trends, indicating that long-term growth sectors are favored over short-term market fluctuations [3] Group 2 - The adjustments lead to structural reallocation of funds, with passive funds needing to buy newly included stocks and sell those that are removed, creating short-term liquidity premiums for the new entrants [4] - Investors are advised to focus on the underlying fundamentals of companies rather than short-term market movements, as long-term valuations depend on the companies' growth potential [4] - The adjustments are not isolated events but part of a broader market trend, emphasizing the importance of understanding the underlying rules of index composition and industry transformation [4]

Core Viewpoint - As of January 7, a total of 137 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Huaneng Hydropower, which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Meike Home, Aiko Photonics, ST Renfu, Yibai Pharmaceutical, Fenglong Co., ST Huapeng, Fuanna, and Yuanxin Industrial [1]

據名單顯示，芯源微(688037.SH)調入中證500指數，明月鏡片(301101.SZ)調入中證1000指數，華大智造 (688114.SH)調入中證A500指數；ST人福(600079.SH)調出中證500及中證A500指數，芯源微調出中證 1000指數。 | | 指数代码 | 指数简称 | 证券代码 | 证券简称 | | --- | --- | --- | --- | --- | | 调入 | 000852 | 中证1000 | 301101.SZ | 明月镜片 | | | 000905 | 中证500 | 688037.5H | 芯濃微 | | | 000510 | 中iFA500 | 688114.SH | 华大智造 | | 増品 | 000852 | 中证1000 | 688037.SH | 芯源微 | | | 000905 | 中证500 | 600079.SH | ST人福 | | | 000510 | 中证A500 | 600079.SH | ST人福 | 智通財經APP獲悉，1月6日，中證指數發佈公告，根據指數臨時調樣規則及編制方案，中證指數有限公 司決定調整中證1000、中證500和中證 ...

【中证指数：中证1000等指数样本临时调整】智通财经1月6日电，中证指数1月6日公告，根据指数临时 调样规则及编制方案，中证指数有限公司决定调整中证1000、中证500和中证A500指数样本，于2026年 1月9日收市后生效。据名单显示，芯源微调入中证500指数，明月镜片调入中证1000指数，华大智造调 入中证A500指数；ST人福调出中证500及中证A500指数，芯源微调出中证1000指数。 转自：智通财经 ...

（文章来源：每日经济新闻） 每经AI快讯，1月6日，中证指数今日发布公告，根据指数临时调样规则及编制方案，中证指数有限公 司决定调整中证1000、中证500和中证A500指数样本，于2026年1月9日收市后生效。据名单显示，芯源 微调入中证500指数，明月镜片调入中证1000指数，华大智造调入中证A500指数；ST人福调出中证500 及中证A500指数，芯源微调出中证1000指数。 ...

Core Viewpoint - The announcement by China Securities Index Co., Ltd. on January 6 indicates adjustments to the sample stocks of the CSI 1000, CSI 500, and CSI A500 indices, effective after market close on January 9, 2026 [1] Group 1: Index Adjustments - Chipone Technology is added to the CSI 500 index [1] - Mingyue Lens is added to the CSI 1000 index [1] - BGI Genomics is added to the CSI A500 index [1] Group 2: Exclusions from Indices - ST Renfu is removed from both the CSI 500 and CSI A500 indices [1] - Chipone Technology is removed from the CSI 1000 index [1]

Core Viewpoint - The company has received approval for clinical trials of HW221043 tablets, a new molecular entity aimed at treating advanced solid tumors, marking a significant step in its drug development process [1][2]. Group 1: Drug Development - The drug HW221043 is classified as a Class 1 chemical drug and is intended for clinical trials in patients with advanced solid tumors [1]. - The total research and development investment for HW221043 has reached approximately 24 million RMB [2]. - The company plans to initiate clinical research following the receipt of the clinical trial approval and will submit trial data to the National Medical Products Administration for production approval after completion [2]. Group 2: Regulatory Approval - The National Medical Products Administration has granted the clinical trial approval for HW221043, confirming that it meets the necessary registration requirements [1]. - The approval was based on the review conducted on October 29, 2025, allowing the drug to proceed with clinical trials [1].

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]

Core Viewpoint - ST Renfu (600079) announced the approval of its drug HW221043 for clinical trials, marking a significant step in its development of a new treatment for advanced solid tumors [1] Group 1: Company Developments - ST Renfu's wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration for HW221043 [1] - HW221043 is a new molecular entity developed independently by the company, with no similar drugs approved for market in China or abroad [1] - The total research and development investment for HW221043 has reached approximately 24 million yuan [1]